Unfractionated heparin
60 U/kg bolus, then 12 U/kg per hour adjusted to an activated partial thromboplastin time of 50 to 70 seconds
Primary Endpoint: Death/MI at 30 days
SYNERGY PCI A Subset analysis of the SYNERGY trial
4,687 high-risk ACS patients undergoing PCI after randomization to unfractionated heparin or enoxaparin
Enoxaparin
1mg/kg sc every 12 hours plus additional 0.3 mg/kg IV at time of PCI if procedure was more than 8 hrs after last sc dose
SYNERGY PCI
Death / MI by intent-to-treat analysis at 30 days
%
Death
MI
Death or MI
P=NS
P=NS
P=NS
SYNERGY PCI
Bleeding in the intent-to-treat analysis at 30 days
%
GUSTO severe
TIMI major
TIMI minor
P<0.05
SYNERGY PCI
Among high-risk ACS patients undergoing PCI, the rate of death/MI at 30 days was not significantly different between patients treated with enoxaparin or unfractionated heparin.
Primary endpoint data for PCI patients is consistent with primary SYNERGY trial
As in primary SYNERGY trial, enoxaparin was associated with an increase in TIMI major bleeding